U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

July 13, 2018 First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration

A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+

A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+

May 22, 2018 Study Finds Prevnar 13 was Associated With Reduced Risk of Hospitalization From Vaccine-Type Community-Acquired Pneumonia in Older Adults1 NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that results from a study analyzing real-world effectiveness data found that

Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine

Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine

May 22, 2018 RSV affects 33 million children globally and leads to approximately 120,000 childhood deaths every year1 In the United States approximately 177,000 older adults are hospitalized annually because of RSV2 The clinical program aims to develop a vaccine

LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

Thursday, May 17, 2018 – 8:00 am EDT Pfizer Inc. (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy

Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO

DATA SPAN 13 THERAPIES ACROSS 16 TYPES OF CANCER AIMED AT TRANSFORMING PATIENT CARE Wednesday, May 16, 2018 – 5:00 pm EDT Pfizer Inc. today announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be

Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

RETACRIT, THE FIRST U.S. BIOSIMILAR ERYTHROPOIESIS-STIMULATING AGENT (ESA), NOW APPROVED ACROSS ALL INDICATIONS Tuesday, May 15, 2018 – 2:38pm EDT Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar

Notice Regarding EpiPen auto-injector supply

Meridian, a subsidiary of Pfizer that manufactures EpiPen auto-injectors, has experienced intermittent constraints affecting U.S. supply. The U.S. Food and Drug Administration (FDA) has posted a supply notification on its website about EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen

Dawn Rogers Appointed Executive Vice President of Pfizer Worldwide Human Resources

NEW YORK, N.Y., April 30 – Pfizer Inc. (NYSE:PFE) today announced that Dawn Rogers will become Executive Vice President of Worldwide Human Resources, effective June 1, 2018. She is currently Senior Vice President of Human Resources for the Chief Operating

Pfizer Hosts Annual Meeting of Shareholders

DECLARES 34-CENT SECOND-QUARTER 2018 DIVIDEND Thursday, April 26, 2018 – 1:13pm EDT The board of directors of Pfizer Inc. today declared a 34-cent second-quarter 2018 dividend on the company’s common stock, payable June 1, 2018, to shareholders of record at the

MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy

Monday, April 23, 2018 – 7:30am EDT Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved MYLOTARG™ (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated,

Pfizer Provides Update on Proposed Trastuzumab Biosimilar

Monday, April 23, 2018 – 7:45am EDT Pfizer Inc. (NYSE:PFE) today announced that it received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) in response to the Biologics License Application for the company’s proposed trastuzumab

Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years

Monday, April 23, 2018 – 8:00am EDT Pfizer Inc. (NYSE: PFE) today announced that TRUMENBA® (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB)